Landiolol

RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia. RAPIBLYK is a beta adrenergic blocker indicated for the short-term reduction of ventricular rate in: adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia.

RAPIBLYK is a selective beta-1-adrenoreceptor antagonist that inhibits the positive chronotropic effects of the catecholamines, epinephrine and norepinephrine, on the heart, where beta-1-receptors are predominantly located. Landiolol does not exhibit any membrane-stabilizing activity or intrinsic sympathomimetic activity at the approved recommended dosage in vitro.

Administer as an intravenous infusion in a monitored setting. Titrate according to ventricular rate. If normal cardiac function, start at 9 mcg/kg/min, adjust dose in 10-minute intervals as needed in increments of 9 mcg/kg/min to a maximum of 36 mcg/kg/min. If impaired cardiac function, start at 1 mcg/kg/min, adjust dose in 15-minute intervals as needed in increments of 1 mcg/kg/min to a maximum of 36 mcg/kg/min.

RAPIBLYK is contraindicated in patients with: Severe sinus bradycardia, sick sinus syndrome, heart block greater than first degree. Decompensated heart failure. Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest. Pulmonary hypertension: May precipitate cardiorespiratory decompensation. Hypersensitivity reactions, including anaphylaxis, to landiolol or any of the inactive ingredients

Risk of hypotension, bradycardia, and cardiac failure: Monitor for signs and symptoms of cardiovascular adverse effects. Reduce or discontinue use. Risk of exacerbating reactive airway disease. Diabetes mellitus: May mask symptoms of hypoglycemia and alter glucose levels, monitor. Monitor for signs of myocardial ischemia when abruptly discontinuing in patients with coronary artery disease

The most common adverse reaction (9.9%) is hypotension.

Negative Inotropes and Chronotropes: Avoid. Sympathomimetics, Positive Inotropes and Vasoconstrictors: Avoid. Catecholamine Depleting Drugs: Monitor blood pressure and heart rate.

Store unreconstituted product at 20°C to 25°C (68ºF to 77ºF), with excursions permitted to 15ºC to 30ºC (59ºF to 86ºF). Store in the original carton to protect from light.